Evaluation of the Treatment of Pregnant Women with COVID-19 Using the Drug Baricitinib

Abstract

This article discusses the complexities and various aspects related to the treatment of pregnant women with COVID-19. The experience of Chinese doctors who were the first to face this problem is considered, and a new method of treating the disease using the drug Baricitinib is also considered. Baricitinib is an anti-inflammatory drug, a representative of the Janus kinase class, used in the treatment of rheumatoid arthritis. It blocks intracellular signaling pathways, which leads to the regulation of the synthesis of interleukins 2, 6, 10, and interferon-gamma. The drug is licensed for the treatment of rheumatoid arthritis, has good efficacy and safety indicators. Attention was paid to the doses and modes of use of baricitinib. The article discusses a study conducted by Chinese doctors. The study involved 34 infected pregnant women, of whom half were offered standard treatment and the other half standard treatment with baricitinib. In order to have a complete picture that allows us to conclude that this method of treatment is ineffective or effective, it is necessary to continue monitoring patients who took baracitinib in the treatment of COVID-19.